Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Nov 5;17(44):60104-60125.
doi: 10.1021/acsami.5c18100. Epub 2025 Oct 27.

Peptide-Based Targeted Covalent Inhibitors

Affiliations
Review

Peptide-Based Targeted Covalent Inhibitors

Fangyu Cao et al. ACS Appl Mater Interfaces. .

Abstract

Covalent inhibitors are one of many conventional covalent drugs and have garnered wide attention for their breakthrough advancements in overcoming drug resistance and improving selectivity. Among the component species for covalent inhibitors, peptide moieties have been broadly utilized to develop covalent inhibitors through serving as ligands to delivery vehicles, due to their advantages of large binding interfaces, reliable associating affinity, and excellent biocompatibility. Incorporating peptide ligands with electrophilic warheads with controllable reactivity leads to covalent inhibitors targeting specific proteins and mitigating off-target concern. However, inherent limitations such as poor membrane permeability and insufficient in vivo stability have constrained their clinical translation, necessitating the development of advanced delivery systems. Concurrently, self-assembly of peptides into nanostructures driven by noncovalent interactions gives rise to potential platforms to deliver covalent inhibitors and release them at targeting pathological sites, thus allowing for precise control of covalent inhibition. In this review, we systematically summarize recent progress in covalent inhibitors containing peptide ligands or delivered by peptide assemblies. Starting with the structure and activity mechanism of targeted covalent inhibitors, we introduce the design strategies for conventional peptide covalent inhibitors and their applications in disease-related targets. Following a brief discussion of the advance in controllable reactive electrophilic warheads, we highlight the delivery systems and the role of supramolecular assemblies in inducing proximity between noncovalent ligands and warheads. Eventually, we discuss the current challenges in clinical transformation and future development of covalent inhibitors, providing perspective for the development of the next generation of covalent drugs.

Keywords: covalent drugs; disease therapy; drug delivery; peptides; stimuli-responsiveness.

PubMed Disclaimer

LinkOut - more resources